121 related articles for article (PubMed ID: 32692734)
61. [Reports from the ASCO GI 2007, Gastrointestinal Cancers Symposium, Orlando, Florida].
Tumori; 2007; 93(2):suppl 25-53. PubMed ID: 17557585
[No Abstract] [Full Text] [Related]
62. [What's new in 2009 in prostate cancer: highlights from ASTRO, EAU, ASCO and AUA meetings].
Salomon L; Peyromaure M; Mongiat-Artus P; Roset F; Gachignard N; Bastide C; Richaud P; Beuzeboc P; Cornud F; Molinié V; Soulié M; Benchikh El Fegoun A;
Prog Urol; 2010 Mar; 20 Suppl 1():S61-7. PubMed ID: 20493449
[TBL] [Abstract][Full Text] [Related]
63. Dose-volume analysis and the temporal nature of toxicity with stereotactic body radiation therapy for prostate cancer.
Seymour ZA; Chang AJ; Zhang L; Kirby N; Descovich M; Roach M; Hsu IC; Gottschalk AR
Pract Radiat Oncol; 2015; 5(5):e465-e472. PubMed ID: 25795252
[TBL] [Abstract][Full Text] [Related]
64. Burden of metastatic bone disease from genitourinary malignancies.
Mulders PF; Abrahamsson PA; Bukowski RM
Expert Rev Anticancer Ther; 2010 Nov; 10(11):1721-33. PubMed ID: 21080800
[TBL] [Abstract][Full Text] [Related]
65. Proceedings of the 2013 ASCO Gastrointestinal Cancers Symposium, January 24-26, 2013, San Francisco, CA, USA.
JOP; 2013 Mar; 14(2):119-217. PubMed ID: 24006522
[No Abstract] [Full Text] [Related]
66. Proceedings of the 2012 ASCO Gastrointestinal Cancers Symposium, January 19-21, 2012, San Francisco, CA, USA.
JOP; 2012 Mar; 13(2):131-186. PubMed ID: 22787717
[No Abstract] [Full Text] [Related]
67. Proceedings of the 2011 ASCO Gastrointestinal Cancers Symposium. January 20-22, 2011,San Francisco, CA, USA.
JOP; 2011 Mar; 12(2):83-125. PubMed ID: 21812121
[No Abstract] [Full Text] [Related]
68. Scientific Advancements in Drug Development and Trials for Urothelial Carcinoma: Insights From the 2023 ASCO-GU Cancers Symposium.
Feng D; Li D; Wu R; Han P
Aging Dis; 2023 Dec; 14(6):1953-1957. PubMed ID: 37199595
[No Abstract] [Full Text] [Related]
69. ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review and meta-analysis.
Urun Y; Leow JJ; Fay AP; Albiges L; Choueiri TK; Bellmunt J
Crit Rev Oncol Hematol; 2017 Dec; 120():120-126. PubMed ID: 29198325
[TBL] [Abstract][Full Text] [Related]
70. Joint genitourinary cancer symposium between Egyptian and American centers.
Zaghloul MS
Expert Rev Anticancer Ther; 2011 May; 11(5):697-9. PubMed ID: 21554043
[TBL] [Abstract][Full Text] [Related]
71. Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement.
Chen RC; Rumble RB; Loblaw DA; Finelli A; Ehdaie B; Cooperberg MR; Morgan SC; Tyldesley S; Haluschak JJ; Tan W; Justman S; Jain S
J Clin Oncol; 2016 Jun; 34(18):2182-90. PubMed ID: 26884580
[TBL] [Abstract][Full Text] [Related]
72. Neuroendocrine tumors of the pancreas: what's new. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
Dimou AT; Syrigos KN; Saif MW
JOP; 2010 Mar; 11(2):135-8. PubMed ID: 20208321
[TBL] [Abstract][Full Text] [Related]
73. Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update.
Kalemkerian GP; Narula N; Kennedy EB; Biermann WA; Donington J; Leighl NB; Lew M; Pantelas J; Ramalingam SS; Reck M; Saqi A; Simoff M; Singh N; Sundaram B
J Clin Oncol; 2018 Mar; 36(9):911-919. PubMed ID: 29401004
[TBL] [Abstract][Full Text] [Related]
74. [Immuno-, radio-, and chemotherapeutic studies in head and neck cancer : Highlights of the ASCO Annual Meeting 2017].
Schuler PJ; von Witzleben A; Doescher J; Wollenberg B; Dietz A; Hoffmann TK
HNO; 2018 Mar; 66(3):212-218. PubMed ID: 29460015
[TBL] [Abstract][Full Text] [Related]
75. [ASCO-update 2015 - highlights of the 51. meeting of the american society of clinical oncology/ASCO 2015].
Lorenzen S; Arnold D; Fottner C; Leichsenring J; Moehler M; Seufferlein T; Vogel A; Weber MM; Reinacher-Schick A
Z Gastroenterol; 2016 Feb; 54(2):167-72. PubMed ID: 26854837
[TBL] [Abstract][Full Text] [Related]
76. Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion.
Virgo KS; Basch E; Loblaw DA; Oliver TK; Rumble RB; Carducci MA; Nordquist L; Taplin ME; Winquist E; Singer EA
J Clin Oncol; 2017 Jun; 35(17):1952-1964. PubMed ID: 28441112
[TBL] [Abstract][Full Text] [Related]
77. Docetaxel in the management of breast and non-small-cell lung cancers. ASCO 2000, 22nd annual San Antonio Breast Cancer Symposium, and ECCO 10. Abstracts.
Oncology (Williston Park); 2000 Aug; 14(8 Suppl 7):7-47. PubMed ID: 11021302
[No Abstract] [Full Text] [Related]
78. The impact of taxanes on the management of genitourinary cancers.
Balar AV
Anticancer Drugs; 2014 May; 25(5):555-60. PubMed ID: 24525590
[TBL] [Abstract][Full Text] [Related]
79. Poster Exhibit 2: Non-prostate Genitourinary Cancers.
Can Urol Assoc J; 2021 Jun; 15(6 Suppl 2):S84-S98. PubMed ID: 34162473
[No Abstract] [Full Text] [Related]
80. Non-prostate Genitourinary Cancers, Tuesday, June 29, 2021.
Can Urol Assoc J; 2021 Jun; 15(6 Suppl 2):S58-S62. PubMed ID: 34162470
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
